These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 28376458)
21. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease. Shiffman D; Slawsky K; Fusfeld L; Devlin JJ; Goss TF Clin Ther; 2012 Jun; 34(6):1387-94. PubMed ID: 22560621 [TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of population-based screening for diabetes and hypertension in India: an economic modelling study. Kaur G; Chauhan AS; Prinja S; Teerawattananon Y; Muniyandi M; Rastogi A; Jyani G; Nagarajan K; Lakshmi P; Gupta A; Selvam JM; Bhansali A; Jain S Lancet Public Health; 2022 Jan; 7(1):e65-e73. PubMed ID: 34774219 [TBL] [Abstract][Full Text] [Related]
23. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations. Logman JF; Heeg BM; Herlitz J; van Hout BA Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780 [TBL] [Abstract][Full Text] [Related]
24. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly. Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556 [TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of population-based vascular disease screening and intervention in men from the Viborg Vascular (VIVA) trial. Søgaard R; Lindholt JS Br J Surg; 2018 Sep; 105(10):1283-1293. PubMed ID: 29691840 [TBL] [Abstract][Full Text] [Related]
26. Priorities among effective clinical preventive services: results of a systematic review and analysis. Maciosek MV; Coffield AB; Edwards NM; Flottemesch TJ; Goodman MJ; Solberg LI Am J Prev Med; 2006 Jul; 31(1):52-61. PubMed ID: 16777543 [TBL] [Abstract][Full Text] [Related]
27. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Gaziano TA; Opie LH; Weinstein MC Lancet; 2006 Aug; 368(9536):679-86. PubMed ID: 16920473 [TBL] [Abstract][Full Text] [Related]
28. Repeated tobacco-use screening and intervention in clinical practice: health impact and cost effectiveness. Solberg LI; Maciosek MV; Edwards NM; Khanchandani HS; Goodman MJ Am J Prev Med; 2006 Jul; 31(1):62-71. PubMed ID: 16777544 [TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of hypertension therapy according to 2014 guidelines. Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742 [TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Greving JP; Buskens E; Koffijberg H; Algra A Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010 [TBL] [Abstract][Full Text] [Related]
31. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis. Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM; Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147 [TBL] [Abstract][Full Text] [Related]
32. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy. Ess SM; Szucs TD Ital Heart J; 2001 Mar; 2(3):181-8. PubMed ID: 11305529 [TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of the 2014 U.S. Preventive Services Task Force (USPSTF) Recommendations for Intensive Behavioral Counseling Interventions for Adults With Cardiovascular Risk Factors. Lin J; Zhuo X; Bardenheier B; Rolka DB; Gregg WE; Hong Y; Wang G; Albright A; Zhang P Diabetes Care; 2017 May; 40(5):640-646. PubMed ID: 28213373 [TBL] [Abstract][Full Text] [Related]
34. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Maciosek MV; Solberg LI; Coffield AB; Edwards NM; Goodman MJ Am J Prev Med; 2006 Jul; 31(1):72-9. PubMed ID: 16777545 [TBL] [Abstract][Full Text] [Related]
36. Integrated screening and treatment services for HIV, hypertension and diabetes in Kenya: assessing the epidemiological impact and cost-effectiveness from a national and regional perspective. Kasaie P; Weir B; Schnure M; Dun C; Pennington J; Teng Y; Wamai R; Mutai K; Dowdy D; Beyrer C J Int AIDS Soc; 2020 Jun; 23 Suppl 1(Suppl 1):e25499. PubMed ID: 32562353 [TBL] [Abstract][Full Text] [Related]
37. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. Hay JW; Sterling KL Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088 [TBL] [Abstract][Full Text] [Related]